Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling

Takeda has launched ORZEYFUL, a first-in-class orexin agonist for Narcolepsy Type 1, in Japan and China after receiving approvals from regulatory authorities. The drug, discovered by Takeda scientists, is the lead product in their orexin franchise aimed at treating sleep-wake disorders. ORZEYFUL is set to launch in the U.S. next month following DEA scheduling, with additional Health Authority submissions in progress globally.